Thymosin Alpha-1 guide & protocols

Thymosin Alpha-1 has a stronger regulatory footprint than almost anything else on this site. It's an approved prescription medicine in dozens of countries, used for chronic hepatitis and as immune support alongside other treatment, and it comes with something this market rarely provides: a dosing standard set by a regulator rather than by a forum. That standard is 1.6 mg, and once you know it, the odd numbers on vendor pages start making sense.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target amount you're working with.

What it is

Thymosin Alpha-1 is a 28-amino-acid peptide your thymus makes. The thymus is the gland that trains T-cells, the part of the immune system that recognises specific threats, and it is also the organ that shrinks steadily from adolescence onward. By midlife it's a fraction of what it was, and the decline in immune function that comes with age is tied to that.

What this compound does is push T-cells toward maturing and responding, rather than suppressing anything. That direction matters and it's the thing most worth understanding on this page: nearly every other peptide people take for immune reasons calms inflammation down. This one wakes a response up. They are not interchangeable, and in some situations they're opposites.

It's approved and prescribed in a long list of countries, though not in the United States, where it has orphan drug designation but no general approval.

What people use it for

The immune decline that comes with age is the main reason people in this audience arrive. The reasoning is direct: the thymus has shrunk, this is the thymus's own signalling peptide, and the hope is that supplying it does something about the consequence. That's a coherent argument and it's largely untested in healthy people.

Recurrent infection is the practical version of the same thing: the person who catches everything going round, whose colds last three weeks, who never quite recovered from the last thing.

The approved uses are different and worth knowing: chronic hepatitis B and C, and immune support alongside cancer treatment or serious infection. Those are the settings the evidence comes from, and they are a long way from a healthy adult wanting fewer colds.

Formulations

Thymosin Alpha-1 ships as a lyophilized powder for subcutaneous injection. Across the vendors we track, 10 mg vials dominate with 5 mg the common alternative.

The approved pharmaceutical product comes as a 1.6 mg vial, one vial per dose. That's the number worth carrying in your head, because it means a 10 mg research vial is a little over six standard doses and a 5 mg vial is roughly three. The research market sells this compound in multiples of a clinical dose without ever mentioning what the clinical dose is.

Dosing protocols

Unusually for this site, the top row is a regulator's figure rather than a convention, and the market's own numbers cluster sensibly around it.

See the Thymosin Alpha-1 research notes for the research behind these figures.

All patterns above are subcutaneous injection.

Why 1.6 mg, and why it's a useful anchor

The approved figure isn't weight-adjusted and isn't a range, which is unusual in itself. It's a fixed 1.6 mg per dose, twice a week, and it has been used that way in patients for years across many countries. That gives this compound something almost nothing else here has: a number with real institutional weight behind it, at a frequency, over a defined course.

What it doesn't give you is evidence for the use you probably have in mind. The 1.6 mg standard was established for chronic viral hepatitis. Nobody has run the equivalent work in healthy adults wanting better immune function in midlife. So the amount is well-founded and the indication is borrowed, and it's worth being clear-eyed that those are different things.

Amount total, for planning your vial purchase. At 1.6 mg twice weekly, a month is 12.8 mg and a three-month course is about 38 mg, so four 10 mg vials. That's a genuinely modest running cost for a compound with this much clinical history behind it.

How much to reconstitute at once. A reconstituted vial keeps about 28 days refrigerated, and twice-weekly dosing uses 12.8 mg in that window, so a 10 mg vial is comfortably consumed inside it and a 5 mg vial lasts under two weeks. Working example: 10 mg into 2 mL of bacteriostatic water gives 5,000 mcg per mL, so a 1.6 mg dose is 1,600 divided by 5,000, times 100, which is 32 units on a standard U-100 insulin syringe. See how much to reconstitute at once for the general math.

Cycling guidelines

The approved use runs for months continuously rather than in short cycles, which is a different shape from most of this site. Courses of six months appear in the hepatitis setting.

In general immune use, three months on with a break after is the pattern most often described, and it has nothing behind it. There's no tolerance mechanism proposed, so the argument for stopping isn't pharmacological, it's the ordinary one about not taking something indefinitely when the long-run picture in healthy people is unknown.

Signs a course is commonly stopped or reconsidered:

• Injection site reactions, which are the most commonly reported effect
• Any flare of an existing autoimmune condition, which is the one on this list that matters most and is explained below
• Fatigue or a flu-like feeling in the first days, which is described occasionally and usually settles
• Three months with no discernible change in how often you're getting ill

Stacking

Most commonly paired stack: Thymosin Alpha-1 with KPV or another anti-inflammatory compound.

Rationale, and the caution inside it: the argument is that one sharpens the immune response while the other keeps inflammation in check, which sounds balanced. It's worth noticing that these are opposing directions, and that nobody has studied what running both does. The pairing is intuitive rather than evidenced.

Protocol as run: each on its own schedule, since twice-weekly and once-daily don't line up. Separate injections.

Lighter stacks: glutathione appears on general antioxidant grounds. Vitamin D comes up constantly in the same conversations and has considerably more human evidence behind it for immune function than anything on this page, which is worth saying out loud.

Combinations to approach carefully: immunosuppressant medication, and this is a real one rather than a formality. If you're taking something to hold your immune system down, adding something designed to push it up is working against your own treatment. Anyone in that position should be talking to the prescriber rather than reading a page like this one.

Expected results timeline

First weeks: nothing you'd notice. This isn't a compound with an acute effect, and there's no equivalent of the sleep change people report on the growth hormone peptides.

Months in: where people report anything it's about frequency and duration of illness, and that takes a season to assess honestly. If you're evaluating whether you get fewer colds, you need enough time to have not had them.

Extended use: the approved courses run months, so long use is at least well-characterised in patients even if not in healthy adults.

What to expect realistically: the evidence here is real, substantial and about other people. Years of use in chronic hepatitis, in cancer care, in serious infection, in populations whose immune systems were already in trouble. What has not been studied is whether a healthy adult in midlife who takes this gets ill less often. The mechanism makes it plausible; nothing establishes it, and it's an unusually hard thing to notice in yourself even if it works.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target amount.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe. At 32 units for a standard dose this is a larger draw than most compounds on this site.
4. A subcutaneous site is chosen, commonly the abdomen or thigh, with sites rotated between doses.
5. The skin is pinched and the injection given at roughly a 45-degree angle.
6. Doses are commonly spaced evenly across the week, since the schedule is twice weekly rather than daily.
7. Timing within the day is unconstrained: no meal or sleep dependency.

Side effects and safety

Common: injection site reactions, and little else. The tolerability record on this compound is genuinely good and it comes from years of prescribed use rather than from community reports.

Less common: fatigue or a transient flu-like feeling in the first days, which is at least consistent with a compound that provokes an immune response.

The one that matters: autoimmune conditions. This compound pushes immune activity up, and an autoimmune condition is immune activity aimed at the wrong target. Stimulating it is the wrong direction, at least in principle, and this is the clearest contraindication on the page rather than a generic caution.

What we know, unusually: the safety picture comes from approved use in patients across many countries and years, including people who were seriously unwell. That's a much better basis than most of this site has.

What we don't know: what it does in healthy adults over years, because the studied populations were not healthy. Whether it meaningfully offsets age-related immune decline is the specific open question, and it's the reason most people here are interested.

Contraindications: autoimmune conditions and immunosuppressant therapy, including after an organ transplant, where pushing immune activity up actively opposes the treatment. Pregnancy, breastfeeding and use in minors have no data outside of medical supervision.

Drug interactions: immunosuppressants, as above. Nothing else established.

Thymosin Alpha-1 vs. KPV

These two get shelved together as "immune peptides" and they point in opposite directions, which makes the comparison more useful than most.

Choose Thymosin Alpha-1 if: the problem is catching everything and taking too long to shake it, and you don't have an autoimmune condition.

Choose KPV if: the problem is inflammation, especially gut inflammation, where turning the immune response up is the last thing you want.

See the KPV guide and protocols for its own dosing. Running both is a common suggestion and, as noted above, points two ways at once.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C and protect from light. Kept frozen, the unreconstituted powder is commonly described as stable considerably longer. Take lot-specific stability from the vendor's certificate of analysis.

Reconstituted solution: refrigerate and use within about 28 days, which twice-weekly dosing comfortably fits inside on a 10 mg vial.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or the reconstituted liquid
• Powder that has clumped or gone sticky, which usually means moisture reached it

FAQ

Is it actually approved? In dozens of countries, for chronic hepatitis and immune support. Not in the United States, where it holds orphan designation but no general approval.

Why 1.6 mg? It's the approved product's fixed dose, twice weekly. Research vial sizes are quietly built around it: a 10 mg vial is a little over six doses.

Will it help me get fewer colds? That specific question has not been studied. The evidence is in people with serious illness, and the mechanism makes the extrapolation reasonable rather than established.

Can I take it if I have an autoimmune condition? This is the compound's clearest contraindication. It pushes immune activity up, which is the wrong direction for a condition defined by immune activity aimed at the wrong target.

How long before I'd know? A season, honestly. Judging whether you get ill less often needs enough time to have not been ill.

Thymosin Alpha-1 or KPV? Opposite directions. This one for an under-responsive immune system, KPV for inflammation.

How long do people run it? The approved courses run months. General immune use is commonly described as three months on with a break.

What about thymalin? A related thymic preparation with a much thinner record and, currently, no live pricing in our data.

Bottom line

Key dosing takeaways:

• 1.6 mg twice weekly is the approved standard, and it's one of the few figures on this site set by a regulator rather than a market
• A 10 mg research vial is a little over six standard doses, which is why the odd vial sizes make sense once you know the dose
• The amount is well-founded; the indication most people here have in mind is borrowed from populations who were seriously unwell

Best practices:

• Spacing the two weekly doses evenly rather than clustering them
• Judging a course over a season rather than a fortnight, since the outcome is an absence of illness
• Not taking it at all with an autoimmune condition or on immunosuppressant therapy

Works best for people who:

• Are catching everything and shaking it slowly, rather than dealing with inflammation
• Want the compound on this site with the deepest record of actual prescribed use
• Can hold that the record is real and belongs to a different population than theirs

Research-grade Thymosin Alpha-1 is sold for research, and the clinical record behind it belongs to patients with serious illness rather than to healthy adults. You already know that. You're an adult making an informed call about your own body, and that's yours to make.